Liver Cancer Market Size Worth $10.48 Billion By 2030 | CAGR: 20.0%

Liver Cancer Market Size Worth $10.48 Billion By 2030 | CAGR: 20.0%

The global liver cancer market size is expected to reach USD 10.48 billion by 2030, according to a new study by Polaris Market Research. The report “Liver Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Cholangio Carcinoma, Hepatocellular Carcinoma, Hepatoblastoma, Others); By Treatment Type; By Region; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.


The main drivers influencing the market growth are the rising incidence of liver cancer, increased investments in research & development to create novel medicines, and government programmers to raise cancer awareness. For instance, the Globocan 2020 study estimates that approximately 905,677 new cases of liver cancer were detected worldwide.


Moreover, according to Cancer Research UK, there are around 6,200 new liver cancer cases in the UK each year, or 17 cases every day. With 2% of all new cancer cases, liver cancer is the 18th most prevalent malignancy in the UK. Liver cancer is the 20th most prevalent cancer in women in the UK, with about 2,100 new cases per year.


Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:


Additionally, the market is anticipated to rise due to rising research initiatives and funding, which might lead to the developing of an innovative liver cancer treatment if these studies have successful outcomes. For instance, according to Clinical, NETRIS Pharma and University Hospital, Grenoble collaborated to study on September 23, 2022, will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in the first-line setting in patients with unresectable hepatocellular carcinoma.


The NP137 study medication is being evaluated with atezolizumab-bevacizumab to improve tumor response and survival outcomes while maintaining acceptable safety. The trial officially began in November 2022 and is scheduled to end in November 2024.


Furthermore, a researcher from Australia's Edith Cowan University got USD 2.35 million in funding to support a new type of radiation treatment for liver cancer that will be trialed across Australia over the next five years. Due to the increasing prevalence of liver cancer and associated risk factors and continuous research and development efforts, the market is anticipated to rise rapidly throughout the forecast period.


But throughout the projection period, expansion in the market is anticipated to be constrained by elements including side effects linked to specific pharmaceuticals, the high price of cancer therapies, and strict regulatory environments.


Liver Cancer Market Report Highlights

  • In 2021, hepatocellular carcinoma is expected to rule the liver cancer market. Technological advancement, personalized medicine, and cost-effective treatment options are factors that are anticipated to boost the expansion of the global market for hepatocellular carcinoma treatments.
  • In 2021, the targeted medication therapy category will account for the greatest share of the market. Targeted therapy is proving to be a viable prospective treatment with promising therapeutic effects in a number of cancers.
  • In 2021, the North America accounted for the largest revenue share in 2021. The main factors influencing market expansion in North America are the rising incidence of liver cancer in the area, the presence of sizable market participants, and the development of novel products.
  • The global players with global presence include Abbott Laboratories, F. Hoffmann-La Roche, Bayer AG, Bristol Myers Squibb Company, and Celsion Corporation.


Polaris Market Research has segmented the Liver Cancer Market report based on, type, treatment type, and region:


Liver Cancer, Type Outlook (Revenue - USD Billion, 2018 - 2030)

  • Hepatocellular Carcinoma
  • Cholangio Carcinoma
  • Hepatoblastoma
  • Other Types

Liver Cancer, Treatment Type Outlook (Revenue - USD Billion, 2018 - 2030)

  • Targeted Drug Therapy
  • Immunotherapy
  • Chemotherapy

Liver Cancer, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

License and Pricing

Purchase Report Sections

  • Regional analysis
  • Segmentation analysis
  • Industry outlook
  • Competitive landscape
Request for Discount Pricing